摘要目的 丙戊酸钠、卡马西平、托吡酯被公认为是目前广谱的抗癫(癎)药物,临床上均可用于治疗伴中央-颞区棘波的儿童良性癫(癎)(BECT).本研究旨在比较这些药物对儿童BECT的治疗效果,筛选临床单药治疗的首选药物.方法 通过84例药物治疗BECT病例(丙戊酸钠31例,卡马西平31例,托吡酯22例)的回顾性分析,从首药治疗失败时间、首治发作控制率、药物不良反应三个方面,对托吡酯、卡马西平、丙戊酸钠的治疗效果进行比较.结果 托吡酯、卡马西平、丙戊酸钠的首药治疗失败时间分别为3.00个月[0.75～12.00]、8.00个月[2.50～32.00]、5.00个月[1.25～11.75],三者差异无显著性(P=0.463).癫(癎)发作控制率托吡酯、卡马西平、丙戊酸钠分别为77.3%、83.9%、74.2%,差异无显著性(X2=1.475,P=0.478).托吡酯有较高的药物不良反应发生率,与丙戊酸钠(X2=8.717,P=0.003)和卡马西平(X2=7.105,P=0.008)相比差异有显著性,丙戊酸钠与卡马西平相比差异无显著性(X2=0.111,P=0.74).结论 托吡酯、卡马西平、丙戊酸钠均可作为儿童BECT单药治疗的首选药物.

abstractsObjective To piramate, Carbamazepine and Sodium valproate are generally acknowl-edged to be the current broad-spectrum antiepileptic drugs, which are used for the treatment of BECT. Our study aimed to compare the long-term effects of these drugs in patients with BECT and find the drug for monotherapy. Methods We conducted a retrospective study of 84 children with BECT to compare the thera-peutic effect of Topiramate, Sodium valproate and Carbamazepine by analyzing treatment failure time, seizure control rate and drug adverse effects. Results There was no difference among Topiramate,Sodium valproate and Carbamazepine in treatment failure time (P=0.463) and seizure control rate (X2=1.475, P=0.478), but patients taking Topiramate had a higher incidence of adverse events compared with those taking Sodium valproate(X2=8.717,P=0.003)or Carbamazepine (X2=7.105,P=0.008). Conclusion Topiramate,So-dium valproate and Carbamazepine could be the first antiepileptic drug in children with BECT.